Home
About
Overview
Sharing Data
ORCID
Help
History (14)
Structures of human peptidylarginine deiminase type III provide insights into substrate recognition and inhibitor design.
Risk factors for the incidence and progression of radiographic knee osteoarthritis.
Military use of tranexamic acid in combat trauma: Does it matter?
Prenatal bisphenol A exposure contributes to Tau pathology: Potential roles of CDK5/GSK3?/PP2A axis in BPA-induced neurotoxicity.
Benefits and harms of roflumilast in moderate to severe COPD.
See All 14 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Benefits and harms of roflumilast in moderate to severe COPD.
Yu T, Fain K, Boyd CM, Singh S, Weiss CO, Li T, Varadhan R, Puhan MA. Benefits and harms of roflumilast in moderate to severe COPD. Thorax. 2014 Jul; 69(7):616-22.
View in:
PubMed
subject areas
Aged
Aminopyridines
Benzamides
Cyclopropanes
Female
Humans
Male
Middle Aged
Phosphodiesterase 4 Inhibitors
Placebos
Pulmonary Disease, Chronic Obstructive
Risk Assessment
authors with profiles
Sonal Singh MD, MPH